prevymis 480 mg tabletti, kalvopäällysteinen
merck sharp & dohme limited - eu / 1/17/1245/002 - tabletti, kalvopäällysteinen - 480 mg - letermovirum
lokelma 5 g jauhe oraalisuspensiota varten
astrazeneca ab - eu: n/1/17/1173/001-02 - jauhe oraalisuspensiota varten - 5 g - zirconii cyclosilicas
lokelma 10 g jauhe oraalisuspensiota varten
astrazeneca ab - eu: n/1/17/1173/003-04 - jauhe oraalisuspensiota varten - 10 g - zirconii cyclosilicas
alpivab 200 mg infuusiokonsentraatti, liuosta varten
biocryst uk ltd c/o morgan lewis & bockius - eu: n/1/18/1269/001 - infuusiokonsentraatti, liuosta varten - 200 mg - peramivirum
steglatro 5 mg tabletti, kalvopäällysteinen
merck sharp & dohme limited - eu: n/1/18/1267 - tabletti, kalvopäällysteinen - 5 mg - acidum l-pyroglutamicum
steglatro 15 mg tabletti, kalvopäällysteinen
merck sharp & dohme limited - eu: n/1/18/1267 - tabletti, kalvopäällysteinen - 15 mg - acidum l-pyroglutamicum
steglujan 15 mg / 100 mg tabletti, kalvopäällysteinen
merck sharp & dohme limited - eu: n/1/18/1266/07-012 - tabletti, kalvopäällysteinen - 15 mg / 100 mg - monohydricum phosphatum,ertugliflozinum acidum l-pyroglutamicum
steglujan 5 mg / 100 mg tabletti, kalvopäällysteinen
merck sharp & dohme limited - eu: n/1/18/1266/01-06 - tabletti, kalvopäällysteinen - 5 mg / 100 mg - acidum l-pyroglutamicum,sitagliptinum monohydricum phosphatum
prehevbri
vbi vaccines b.v. - hepatiitti b-pinta-antigeeni - b-hepatiitti - rokotteet - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.
opfolda
amicus therapeutics europe limited - miglustaattia - glykogeenin varastointitaudin tyyppi ii - muut ruoansulatuskanavan ja aineenvaihduntatuotteet - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).